While BioNTech has been performing clinical trials of its personalised cancer vaccines since 2012, it is looking to expand the scale of its trials to reach its target of having the product ready for approval by 2030.
The treatments have been rolled out in trials in early-stage patients, to prevent their cancer from returning. It has also been used in late-stage patients who do not respond well to other therapies. Last year, the firm announced early positive results in a trial combining the vaccines with another cancer treatment called CAR-T.
Back in the summer, former Conservative party leader Sir Iain Duncan Smith told Express.co.uk that Brexit gives the UK the opportunity to “make itself a global centre for medical technology”.
He said: “First of all, we have some of the greatest scientific universities in the world. And we have one of the greatest data sets in the world which is the NHS. Using anonymised data with the best scientists and individuals in the world, this becomes a very attractive option to invest in and do your medical trails, genetic trails…all these things here.
“What the market needs is a proper set of defining regulations, it is not just about deregulation, it is also about setting the terms of regulation.”
Article source: https://www.express.co.uk/news/science/1718206/brexit-biontech-cancer-vaccine-trail-uk-breakthrough